dipyridamole has been researched along with raltitrexed in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Danenberg, PV; Lehman, NL | 1 |
Boyer, CR; Karjian, PL; Neuteboom, ST; Pegram, M; Wahl, GM | 1 |
4 other study(ies) available for dipyridamole and raltitrexed
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dipyridamole; Dose-Response Relationship, Drug; Drug Interactions; Genes, p53; Humans; Phosphodiesterase Inhibitors; Quinazolines; Thiophenes; Thymidine; Tumor Cells, Cultured | 2000 |
Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bromodeoxyuridine; Carrier Proteins; Cell Survival; Colonic Neoplasms; Dipyridamole; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Humans; Membrane Proteins; Nucleoside Transport Proteins; Quinazolines; Thioinosine; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2002 |